Neurogranin Diagnostic Kit Using Antibody Aptamer Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical tools for detecting brain injuries, especially subclinical brain injuries, are subjective, not widely available, not sensitive or specific enough, and too costly, making it difficult to identify patients at risk of progressing to overt stroke and cognitive/motor loss.
Innovation Solution
The use of antibodies and aptamers that specifically bind to neurogranin, allowing for the development of diagnostic kits and methods to measure neurogranin levels in samples, facilitating the detection of brain injuries through ELISA, competitive-binding assays, and fluorescence-activated cell sorting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical tools such as physical exam and imaging (CT Scan or MRI) are used to detect brain injuries, then detection capability is provided, but the tools are subjective, not widely available, not sensitive or specific enough, and too costly
Solution Approach 1:
The patent extracts the detection function from complex imaging equipment (CT/MRI) and physical exams, isolating the specific task of brain injury detection into a simple blood test that measures neurogranin levels. This extraction enables high sensitivity and specificity without requiring expensive, complex, or widely unavailable imaging equipment.
Solution Approach 2:
The patent employs a disposable blood test kit that uses inexpensive reagents (anti-neurogranin antibodies/aptamers, detection antibodies, substrates) to perform detection. This replaces expensive, reusable imaging equipment with cheap, single-use test kits that are easily distributed and do not require complex infrastructure.
2Measurement precision
If current clinical tools are used, then brain injury detection is possible, but subclinical brain injuries cannot be identified
Solution Approach 1:
The patent replaces subjective mechanical assessments (physical exams, imaging interpretation) with an objective biochemical measurement system. The anti-neurogranin antibodies specifically bind to neurogranin protein in blood samples, and the binding is detected through objective colorimetric, fluorescent, or chemiluminescent reactions, eliminating subjectivity and enabling detection of subclinical injuries.
3Measurement precision
If neurogranin detection is implemented, then accurate and sensitive detection of brain injuries is enabled, but diagnostic infrastructure and reagent distribution are required
Solution Approach 1:
The patent segments the diagnostic system into separate, independently manufacturable components: anti-neurogranin capture reagents (antibodies/aptamers), detection antibodies, labeled secondary antibodies, and substrate reagents. Each component can be produced separately using established biotechnology methods and distributed through常规 cold chain logistics, simplifying manufacturing and distribution while maintaining high detection accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and sensitive detection of brain injuries, including subclinical cases, providing a diagnostic and prognostic tool for brain injury, particularly in children and adults at risk of neurological damage.
Implementation Method 1
The present invention is based, at least in part, on the use of antibodies that bind neurogranin. In one embodiment, the use and method of the present invention makes use of an isolated antibody or fragment thereof that specifically binds to neurogranin.
Implementation Method 2
In certain embodiments, the detectable substance is selected from the group consisting of an enzyme; a fluorescent label; a radioisotope; and chemiluminescent label.
Implementation Method 3
In certain embodiments, the detectable substance is selected from the group consisting of an enzyme; a fluorescent label; a radioisotope; and chemiluminescent label.
Implementation Method 4
In certain embodiments, the detectable substance is selected from the group consisting of an enzyme; a fluorescent label; a radioisotope; and chemiluminescent label.
Implementation Method 5
Further disclosed are aptamers that bind neurogranin. Further disclosed is a polynucleotide aptamer that specifically binds neurogranin.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.